Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $240

Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on Revolution Medicines (NASDAQ: RVMD) and increased the price target from $239 to $240. This adjustment reflects a positive outlook on the company's performance.